Literature DB >> 12560922

A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease.

Kazuhide Yamamoto1, Ryo Terada, Ryoichi Okamoto, Youichi Hiasa, Masanori Abe, Morikazu Onji, Takao Tsuji.   

Abstract

BACKGROUND: Although primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) are two independent autoimmune liver diseases, it is sometimes difficult to characterize the variant forms of autoimmune liver disease. A PBC scoring system, in combination with the AIH scoring system may be helpful to characterize such patients.
METHODS: A PBC scoring system was introduced that selected 14 categories characteristic of PBC. One hundred and thirty-four patients with PBC, 31 patients with autoimmune cholangitis (AIC), 22 patients with overlap syndrome, and 48 patients with AIH were included in the study. The AIC patients fulfilled the PBC criteria but were negative for anti-mitochondrial antibody and positive for anti-nuclear antibody. Overlap syndrome patients fulfilled both the PBC and AIH criteria.
RESULTS: The total scores (means +/- SD) for the PBC, AIC, overlap syndrome, and AIH patients were 23.3 +/- 4.7, 9.3 +/- 4.4, 18.0 +/- 5.9, and 3.6 +/- 3.3, respectively. When definite and probable PBC patients were defined as those with a total score of over 17 and 9-17, respectively, all except for 1 patient could be classified as definite or probable PBC. Four of the 48 AIH patients were classified as probable PBC. PBC scores for the variant autoimmune liver diseases showed a wide deviation. Plotting both PBC and AIH scores in a rectangular coordinate enabled us to locate each patient with variant forms according to the deviation from classical PBC or AIH.
CONCLUSIONS: The PBC scoring system might be useful in characterizing the features of variant forms of autoimmune liver disease.

Entities:  

Mesh:

Year:  2003        PMID: 12560922     DOI: 10.1007/s005350300006

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  8 in total

1.  Is the new diagnostic scoring system of Zeniya and colleagues useful for autoimmune liver diseases?

Authors:  Norio Horiike; Morikazu Onji
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

2.  Anti-mitochondrial M2 antibody-positive autoimmune hepatitis.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Kazunori Fugo; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2015-08-20       Impact factor: 2.447

Review 3.  Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis.

Authors:  Christoph Schramm; Ansgar W Lohse
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

4.  Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities.

Authors:  A Gonzalez-Quintela; R Alende; F Gude; J Campos; J Rey; L M Meijide; C Fernandez-Merino; C Vidal
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

Review 5.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 6.  Overlap syndromes: an emerging diagnostic and therapeutic challenge.

Authors:  Pooja Dhiman; Sharad Malhotra
Journal:  Saudi J Gastroenterol       Date:  2014 Nov-Dec       Impact factor: 2.485

Review 7.  Hepatocellular carcinoma and multiple myeloma with elevated globulin: a case report and literature review.

Authors:  Ling Xu; Wei Yang; Ye-Fei Shu; Xiao-Feng Xu
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

Review 8.  Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis.

Authors:  Yan Zhang; Jie Lu; Weiqi Dai; Fan Wang; Miao Shen; Jing Yang; Rong Zhu; Huawei Zhang; Kan Chen; Ping Cheng; Lei He; Chengfen Wang; Ling Xu; Yingqun Zhou; Chuanyong Guo
Journal:  Gastroenterol Res Pract       Date:  2013-12-04       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.